Compound Planning Inc. Has $2.53 Million Stock Holdings in AstraZeneca PLC $AZN

Compound Planning Inc. lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 37.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 32,928 shares of the company’s stock after purchasing an additional 9,014 shares during the quarter. Compound Planning Inc.’s holdings in AstraZeneca were worth $2,526,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AZN. Chapin Davis Inc. increased its holdings in shares of AstraZeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after buying an additional 120 shares in the last quarter. CoreCap Advisors LLC boosted its holdings in shares of AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after acquiring an additional 125 shares in the last quarter. Highline Wealth Partners LLC raised its position in AstraZeneca by 32.0% in the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares during the last quarter. Traub Capital Management LLC boosted its stake in AstraZeneca by 3.3% in the third quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock worth $316,000 after purchasing an additional 130 shares in the last quarter. Finally, Aaron Wealth Advisors LLC boosted its stake in AstraZeneca by 0.6% in the third quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after purchasing an additional 136 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Trading Up 0.9%

Shares of NASDAQ AZN opened at $206.77 on Wednesday. AstraZeneca PLC has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The firm has a market capitalization of $320.68 billion, a P/E ratio of 68.69, a P/E/G ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. The company’s 50 day simple moving average is $128.98 and its 200 day simple moving average is $99.61.

AstraZeneca Announces Dividend

The business also recently disclosed a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date is Friday, February 20th. AstraZeneca’s dividend payout ratio is currently 74.83%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. TD Cowen reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Citigroup started coverage on shares of AstraZeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Wall Street Zen cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Finally, Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.